ID: h-SDA-2026-04-26-gap-debate-20260417-033
Hypothesis
Individual Baseline Variability in p-tau217 Half-Life Dictates Cessation Threshold Personalization
CSF p-tau217 levels reflect a dynamic equilibrium between neuronal tau release and CSF clearance, with significant inter-individual variability in turnover rates.
neurodegeneration
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 3 support✗ 4 oppose
✓ All Quality Gates Passed
🧪 Overview
CSF p-tau217 levels reflect a dynamic equilibrium between neuronal tau release and CSF clearance, with significant inter-individual variability in turnover rates. Baseline-adjusted p-tau217 normalization (personal threshold = individual baseline × treatment-responsive decline trajectory) would more accurately predict when pathology-driven tau phosphorylation has ceased. However, CSF p-tau217 half-life has not been directly measured in humans, and assay variance dominates at low concentrations where personalization is most needed.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["CSF p-tau217<br/>Biomarker Level"]
B["Individual Baseline<br/>Variability in Half-Life"]
C["CST3 Cystatin C<br/>Degradation Rate Modulator"]
D["AQP4 Water Channel<br/>CSF Turnover Rate"]
E["Personalized Cessation<br/>Threshold"]
F["p-tau217 Monitoring<br/>Precision Adjusted"]
G["Biomarker-Guided<br/>Therapeutic Stopping Point"]
A --> B
B --> C
B --> D
C --> E
D --> E
E --> F
G -.->|"defines"| E
style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix3 supports4 contradicts
Supports
CSF tau turnover rates show substantial inter-individual variability in Alzheimer's disease
Supports
Personalized biomarker thresholds improve Alzheimer's clinical trial sensitivity
Supports
Baseline-adjusted endpoints demonstrate superior treatment effect detection in recent trials
Contradicts
CSF p-tau217 half-life has not been directly measured in humans; cited study infers kinetics rather than measuring specific p-tau217 isoforms
Contradicts
AD biomarker trajectories follow sigmoid rather than exponential decline patterns; baseline alone cannot predict individual trajectories
Contradicts
Assay variance (±10-15%) exceeds biological change as p-tau217 approaches normalization, making individual threshold determination unreliable
Contradicts
Inter-individual variability in clearance may swamp phosphorylation-rate variability, overwhelming the proposed personalization mechanism
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CST3
No curated PDB or AlphaFold mapping for CST3 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CST3, AQP4 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CST3, AQP4.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.2818
Events (7d)
1
Price History
▲11.5%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF personalized cessation thresholds are defined as individual baseline p-tau217 concentration multiplied by the treatment-responsive decline trajectory (calculated as % change from baseline at month | Personalized threshold group will show significantly lower rates of biomarker re-elevation (≤10%) compared to fixed threshold group (≥25%) during the 12-month o | — no observation — | pending | 0.48 |
| IF participants with Alzheimer's disease receiving anti-tau immunotherapy are stratified by individual baseline p-tau217 half-life (short <14 days vs. long >28 days, assessed via stable isotope labeli | Participants with longer baseline p-tau217 half-life will demonstrate 40-60% slower decline rates in CSF p-tau217 levels and reach the normalization threshold 5 | — no observation — | pending | 0.55 |
🔮 Falsifiable Predictions (2)
pendingconf 55%
IF participants with Alzheimer's disease receiving anti-tau immunotherapy are stratified by individual baseline p-tau217 half-life (short <14 days vs. long >28 days, assessed via stable isotope labeling kinetics in CSF), THEN those in the long half-life stratum will require significantly longer trea
Predicted outcome: Participants with longer baseline p-tau217 half-life will demonstrate 40-60% slower decline rates in CSF p-tau217 levels and reach the normalization t
Falsification: No significant correlation (r < 0.2, p > 0.05) between baseline p-tau217 half-life and time to biomarker normalization; or short and long half-life groups reach normalization thresholds at equivalent
pendingconf 48%
IF personalized cessation thresholds are defined as individual baseline p-tau217 concentration multiplied by the treatment-responsive decline trajectory (calculated as % change from baseline at month 3), THEN applying these personalized thresholds will demonstrate ≥85% sensitivity for detecting true
Predicted outcome: Personalized threshold group will show significantly lower rates of biomarker re-elevation (≤10%) compared to fixed threshold group (≥25%) during the
Falsification: Fixed absolute thresholds achieve equivalent or superior sensitivity (>85%) and specificity (>80%) for detecting sustained cessation compared to personalized baseline-adjusted thresholds; or personali
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.